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methods
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Stephanie R. Rainey-Smith4,5, Qiao-Xin Li3, Colin L. Masters3, Ralph N. Martins6, Victor L. Villemagne7,8,
Steven J. Collins3 and Hugo Marcel Vanderstichele9*
Abstract
Background: CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment
exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in
CSF extracted using either gravity drip or aspiration.
Methods: Biomarkers for β-amyloidopathy (Aβ1–42, Aβ1–40), tauopathy (total tau), or synapse pathology (BACE1,
Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-
population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild
cognitive impairment, N = 8; Alzheimer’s disease, N = 6).
Results: High biomarker concordance between extraction methods was seen (concordance correlation > 0.85).
Passing Bablock regression defined low beta coefficients indicating high scalability.
Conclusions: Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results
of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of
biomarkers.
Keywords: Cerebrospinal fluid, Amyloid beta, Alzheimer’s disease, Biomarkers, Collection, Concordance
Background
Dementia is a syndrome with a complex pathophysiology,
characterised by a heterogeneous group of clinical features
and pathological hallmarks (e.g., β-amyloidopathy, tauopa-
thy, synapse loss, oxidative stress, inflammation) [1]. In
particular, Alzheimer’s disease (AD) has a long pre-clinical
phase (20–30 years) [2] with pathological detection requir-
ing visualisation of on-going amyloidopathy and tauopathy
in brains of affected subjects, preferably in an early phase
of the disease [3].
Pathological diagnosis can be achieved by regulatory
approved β-amyloid (Aβ)-positron emission tomography
(PET) and Tau-PET imaging methods [4]. PET technol-
ogy is considered a minimally invasive method, with
little to no complications or risks for the subject.
Harmonisation is required between tracers and inter-
pretations performed by the individual investigators.
Furthermore, each tracer utilises a different brain region
as negative control and each has a different specificity
towards Aβ-oligomers [5]. Only visual interpretation of
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scans by trained physicians is presently approved by the
Food and Drug Administration (FDA) [6]. The method
is expensive and requires highly specialised instrumenta-
tion, training, and logistics [7]. Results are used by clini-
cians to estimate Aβ-neuritic plaque density or tangle
load (FDA Tauvid [8]) in adult patients with cognitive
impairment who are being evaluated for AD and other
causes of cognitive decline.
Cerebrospinal fluid (CSF), which surrounds the brain
and the spinal cord, is considered as a “mirror” of the
brain [9]. CSF collection is a minimally invasive proced-
ure, which is safe when performed with care and appro-
priate precautions [10, 11]. Changes in CSF protein
biomarker profiles, when measured accurately, demon-
strate abnormalities at least 20 years prior to the ex-
pected age of onset in dominantly inherited AD
pedigrees [12]; earlier than can currently be detected
with imaging modalities [13]. In the last two decades,
CSF diagnosis of AD has focused especially on the quan-
tification of proteins that have been identified in plaques
and tangles, such as Aβ1–42 and phospho-tau [14, 15].
More recently, other CSF proteins (e.g., alpha-synuclein
[α-synuclein], Neurogranin [Ng], beta-site amyloid pre-
cursor protein cleaving enzyme 1[BACE1], neuropen-
traxin2, neurofilament [NFL]) have revealed the
presence of co-pathologies/co-morbidities in the brain,
such as Lewy bodies or loss of synapses. The latter can
help to predict the rate of future cognitive decline and
will likely provide tools for better stratification of indi-
viduals for inclusion in clinical trials. At the regulatory
level, efforts are on-going in Europe (European Medi-
cines Agency (EMA)) and the USA (FDA) to qualify CSF
proteins for inclusion in clinical trials [16, 17].
CSF AD biomarker analysis, especially for inter-
laboratory comparisons, has previously been hampered
by variabilities across pre-analytical handling, assay de-
sign, and laboratory performance, exacerbated by the ab-
sence of consensus on how to collect, process, and store
CSF [18]. Consequently, considerable differences in ab-
solute concentrations of AD biomarkers are reported by
different centers using the same assay, leading to non-
uniform cut-off values for an identical context of use.
These difficulties have been mitigated by (i) the estab-
lishment of the Alzheimer’s Association quality control
program which has documented a continuous improve-
ment of assay performance by dedicated vendors of the
immunoassays [19], (ii) the release of certified reference
methods for analysis of CSF Aβ1–42 [20] (no reference
materials are available yet for the other CSF proteins),
and (iii) the introduction of automated biofluid analysis
platforms to reduce inter/intra laboratory variation [21].
These achievements have allowed diagnostic laboratories
to establish internal operator training programs and pro-
vide a tool to the assay vendors to harmonise their
results with the current best practice in the field. How-
ever, accurate quantification of CSF proteins still re-
quires extensive standardisation of sample analysis, as
well as standard operating procedures for collection and
storage of CSF [22].
Several guidance papers have been published with the
ultimate goal of generating a consensus on how to han-
dle CSF sample for analysis of Aβ proteins [18, 22, 23].
Except for the most recent guidance [24] (Hansson
et al. The Alzheimer’s association international guide-
lines for handling of cerebrospinal fluid for routine clin-
ical measurements of amyloid β and tau. Alz
Dementia. Submitted), most recommendations were
based on expert opinion rather than experimental evi-
dence. A key issue not considered in detail in the guid-
ance documents is the methodology for CSF collection
through lumbar puncture (LP). During LP, CSF can be
collected by allowing it to drip into the collection tube
(gravity drip) or by aspiration with a syringe (aspiration).
Proponents of gravity drip maintain that when a syringe
is used to aspirate CSF, the extra surface area of the syr-
inge (even when it is polypropylene) may adsorb analytes
and thus influence assay results, while others believe that
if a suitable polypropylene syringe is used, the resulting
assays for AD biomarkers will be unaffected [25]. The
method of CSF collection is an important issue because
taking volumes of CSF greater than 10mL by gravity
drip is time consuming and can be uncomfortable for
patients. Time taken could be an impediment to routine
CSF sampling if higher throughput is desired for both
diagnosis and monitoring of AD. Standardised guidelines
are published for LP CSF extraction [26]; however, these
are yet to provide evidence as to consistency of results
post different extraction methods.
To objectively investigate potential effects of CSF
collection methodology through LP when assaying AD
biomarker concentrations, we provide a detailed com-
parison of gravity drip collection with aspiration using a
polypropylene syringe during the same collection for
each subject. All other pre-analytical and analytical as-
pects of the procedures for sample analysis were identi-
cal. We hypothesised that analyte concentrations would
be unaltered by extraction method, not only for Aβ and
tau proteins, but also for synapse proteins.
Methodology
Participant information
CSF samples from 50 participants of the Australian Im-
aging, Biomarkers and Lifestyle (AIBL) study were col-
lected using aspiration then gravity drip methods during
the same LP visit. Participants were deemed either cog-
nitively normal (CN) (N = 36; 70%), to have mild cogni-
tive impairment (MCI; N = 8; 15%) or to have AD (N =
6; 15%) after clinical and neuropsychological
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assessments, conducted as previously described [27].
Clinical assessment was taken within 6 months of CSF
collection. Data for clinical parameters such as Mini-
Mental State Exam (MMSE), Clinical Dementia Rating
(CDR) score, the AIBL Pre-clinical Alzheimer’s Cogni-
tive Composite (AIBL-PACC), and Apolipoprotein E ε4
(APOE ε4) allele status were available for all participants.
All data represented in this study are cross sectional.
Lumbar puncture
CSF was collected by LP, in the morning, from overnight
fasted participants, using protocols described in detail
elsewhere [28]. Briefly, the LPs were performed with the
subjects in a sitting position, using a Temena (Polyme-
dic®, EU, tamena.com) spinal needle micro-tip (22/
27G × 103mm; CAT 21922–27), or a RapID set pencil
point spinal needle (25G; Smiths Medical ASD, Inc.,
Keene, NH, USA) if there was difficulty with the fine
needle. Initially, up to 6 mL of CSF was aspirated for
routine microbiological/biochemical assessment and
other concurrent studies, then 8mL of CSF was col-
lected by gravity drip into a 15 mL polypropylene tube
(Greiner Bio-One188271, Fisher Scientific, Goteborg,
Sweden), and placed onto wet ice. After gravity collec-
tion, a polypropylene syringe (BD, North Ryde, NSW,
Australia) was then used to aspirate 2 mL of CSF, which
was then transferred to a second Greiner Bio-
One188271 polypropylene tube, on wet ice. Samples
were processed within 1 h by centrifugation (2000 × g,
4 °C, for 10 min) and the supernatant transferred to a
new Greiner Bio-One188271 polypropylene tube before
being aliquoted in 300 μL volumes into Nunc Cryobank
polypropylene tubes (NUN374088, Thermo Fisher,
MA, USA). Samples were stored in liquid nitrogen vapour
tanks and only thawed once, immediately before analysis.
Prior to thawing, CSF was shipped on dry ice to ADx
NeuroSciences and stored at − 80 °C until the biomarker
analysis. The range of time taken to collect the CSF by
gravity was 10–15min and the range for aspiration was
0.5–1min. Parameters of the sample collection and
adverse incidents have been reported previously [28].
Biomarker assay
Samples from the 50 participants were tested for six ana-
lytes in the facilities of ADx NeuroSciences: α-synuclein,
Aβ1–42 (herein reported as Aβ42), Aβ1–40 (herein re-
ported as Aβ40), total tau, BACE-1 and Ng (trunc P75)
(Assay details are described in Table 1). In parallel, all
samples were verified for blood contamination by testing
for haemoglobin (Hb) content using an in-house devel-
oped Hb-assay [29]. The latter is required to allow a
more accurate interpretation of the α-synuclein concen-
trations obtained [30]. Samples from one subject were
added onto each ELISA plate, aimed at reducing inter-
plate variability. Furthermore, for Aβ40 analysis the sam-
ples were pre-diluted 21-fold with the sample diluent
into a predilution plate that was treated with the same
diluent for 30 min (as described previously in [31]). For
all other 5 analytes the samples were directly added into
the antibody-coated plates for analysis. The reported
concentrations were based on duplicate sample measure-
ments for all six analytes except for Aβ42, Aβ40, total
tau, BACE-1, wherein respectively 7, 8, 1, and 2 samples
were tested singly (due to a technical error or too low
remaining volumes). All samples had a value within the
measuring range as defined by the provided calibrators.
Different levels of run-validation acceptance criteria
were integrated in the test procedure. For each test run,
both kit control samples (Positive Control 1 and 2, pre-
pared using lyophilized calibrators) were within the ac-
ceptance range as described on the certificate of analysis
of the kit lot used. Criteria for blank value (OD < 0.100)
and calibrator curves (OD highest calibrator > 1.2) were
approved. In addition, three “in-house” QC samples
(QC1, QC2, QC3) were included in each assay run for
assessment of test run performance. The composition of
the QC samples is based upon neat CSF obtained from a
commercial source. QC1 and QC2 were samples ob-
tained from an individual subject, while QC3 was com-
posed of a pool of two individual CSF samples. Samples
for this purpose were collected retrospectively, and no
clinical diagnosis is available for these samples. After
their preparation (QC1, 2, and 3), samples were ali-
quoted and frozen. Before each run, an aliquot was
thawed and included in the test run (duplicate testing).
PET imaging
Of the 50 samples, 49 had PET-Aβ imaging available ac-
quired using either 11C-Pittsburgh Compound B (PiB;
N = 4), 18F-florbetapir (FBP; N = 15), or 18F-flutemetamol
(FLUTE; N = 30) tracers. The acquisition protocol for
each radioligand has been detailed previously [32–34].
Briefly, a 20-min acquisition was started 50min after
either PiB or florbetapir injection and 90min after flute-
metamol injection. Aβ-amyloid PET scans were spatially
normalised using CapAIBL [35] and the standard
Centiloid (CL) method was applied for quantitation [5].
Participants were classified as PET-Aβ+ if their CL value was
20 or greater; otherwise, they were classed as PET-Aβ−.
Statistical analysis
Clinical and demographic parameters were assessed via
chi-square test (gender, APOE ε4 allele status), general-
ised linear modelling (GLM; age, AIBL-PACC), and
Kruskal-Wallis test (MMSE, CDR score) where appropri-
ate. Biomarker comparisons between the two extraction
methods were conducted using concordance correlations
(CC), Passing Block Regression analyses, and Bland-
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Altman plot analyses. Paired t-tests were computed to
assess possible differences between biomarker levels
between extraction samples, with Box and Whisker plots
demonstrating differences in biomarker means between
clinical classification for both gravity drip and aspiration
samples. Standardised differences between biomarker
levels from aspiration and gravity drip extraction
methods are presented via error bar plot (Fig. 4). Statis-
tical analyses were performed using the R statistical
environment (Version 3.6.1) [36].
Results
Cohort demographics
From a total of 50 participants who underwent both
gravity drip and aspiration CSF extraction protocols, 49
had PET-Aβ imaging, of which 23 were PET-Aβ+. Of
the CN group, 35% were PET-Aβ+, while 71% and 100%
of MCI and AD participants respectively were PET-Aβ+.
There were no differences in the proportion of males to
females, the proportion of APOE ε4 allele carriage, or
age between the three clinical classification groups. As
expected, participants with either MCI or AD had
significantly lower MMSE scores and significantly higher
CDR scores (Table 2).
Assay characteristics and performance
Table 1 shows the analytical performance characteristics
for each biomarker assay. The means for the intra-assay
percent coefficient of variation (%CV, standard deviation
[SD]) based on duplicate clinical samples were 3.6 (3.0)%








Technology Sandwich ELISA (colorimetric)
Vendor Euroimmun Euroimmun Euroimmun Euroimmun Euroimmun Euroimmun
































Sample Incubation Sample volume
(μL)
15 15 25 15 15 25
Detector volume
(μL)
100 100 100 100 100 100
Incubation time (h) 4 4 4 4 4 4
Incubation
temperature (°C)
18–25 18–25 18–25 18–25 18–25 18–25
Sample dilution
factor (1:x)
21 No dilution No dilution No dilution No dilution No dilution
Run validation data %CV QC samples
(n = 3; min-max)
9.6–14.5 4.5–20.8 9.5–10.2 3.6–6.4 5.9–12.4 4.3–5.8
%CV Kit controls
(n = 2; min-max)
6.0–9.3 2.6–5.0 3,3–7.7 4.1–4.3 4.1–8.1 3.8–3.9
Intra-assay CV (%)
(n = 2; min-max)
0.0–15.3 0.0–23.6 0.0–17.3 0.0–12.9 0.0–8.8 0.0–12.7
Calibrator Calibrator range
(pg/mL)
54–986 81–1724 56–1552 53–1799 238–11,212 150–5988
Sample concentration
range (pg/mL)
p5 3785 188 251 154 1098 1226
p25 5933 383 342 229 1647 1742
p50 8500 589 405 350 2091 2311
p75 10,529 882 529 472 2904 2952
p95 13,542 1272 812 745 3583 4190
Minimum 2431 92 186 115 940 1085
Median 8501 589 405 349.5 2091.5 2311.5
Maximum 18,307 1592 922 1194 5172 5388
Abbreviations: Aβ amyloid beta, mAb monoclonal antibody, p5 percentile 5, pg/mL picograms/milliltre, CV coefficient of variation, μL microlitre
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for Aβ42, 2.1 (1.79)% for Aβ40, 3.0 (2.6)% for Tau, 3.7
(3.2)% for Neurogranin, 3.4 (2.9)% for α-synuclein, and
3.6 (3.0)% for BACE1.
Run-acceptance
All kit control concentrations were within the accept-
ance range for all assays and test runs. OD values for
each calibrator concentration were within the standard
acceptance criteria. The blank value and highest calibra-
tor point were within specification for all analytes over
all test runs. Furthermore, monitoring of the QC
samples revealed an inter-assay variability between 5.0%
(lowest %CV for Neurogranin) and 14.9% (highest %CV
for total Tau; see also results in Table 1).
Biomarker concordance correlations between CSF
extraction methods
Using the six biomarkers that were measured, along with
the three ratios (Aβ42/40, Aβ42/Tau, and (Aβ42/40)/
Tau) for all 50 participants, concordance correlations
(CC) were all greater than 0.85 (Fig. 1). Strongest con-
cordance correlations (CC > 0.95) for individual bio-
markers between extraction methods were found for
Tau (0.993 [95% confidence interval (CI) 0.988–0.996]),
α-synuclein (0.995, [0.991–0.997]), BACE1 (0.987
[0.977–0.992]), Neurogranin (0.985 [0.976–0.991]), and
Aβ42 (0.951 [0.915–0.972]). Of the three ratios, Aβ42/
Tau had the highest CC (0.966 [0.942–0.981]).
Further testing of the concordance via the Passing
Bablock method defined regression equations and plots
(Supplementary Figure 1) for the relationship between
extraction methods. For each biomarker, the plot shows
the linear relationship, with thin bootstrap confidence
intervals defining small variation between the extraction
methods. For individual biomarkers, BACE1, Tau, α-
synuclein, and Neurogranin had the smallest confidence
intervals, indicating a close fit between the two measure-
ments, whist for the ratio biomarkers the confidence
intervals spread wider, with larger biomarker values
indicating an increased variance in the fit amongst the
larger ratio values.
Assessment of concordance via Bland-Altman plots
Each of the nine biomarkers (six individual biomarkers
and three biomarker ratios) showed a reasonable spread
of data points, with plots showing markers having only
either one, two, or three points that fit outside ±1.96SD
around zero (Fig. 2). Disregarding the outliers, symmetry
around the zero-difference line for each individual bio-
marker was maintained. Lower mean levels for the ratio
biomarkers (Aβ42/40)/Tau and Aβ42/Tau demonstrated
smaller differences between extraction methods, while
larger mean differences showed larger spread of the data.
Of the outliers, six participant samples were responsible
for all values outside the ± 1.96SD lines. The participant
with a large negative difference for BACE1 (− 457.7) also
had a large negative difference for Tau (− 78.4). Another
participant with unusually high BACE1 values (> 4500)
also had a large difference for Tau (− 58.8). The sample
with the largest negative difference for Aβ42/40 (− 0.04)
also had the largest negative difference for (Aβ42/40)/
Tau (− 1.742).
Paired sample comparisons
Comparing biomarkers via both the complete sample
and stratified by clinical classification showed no signifi-
cant difference in mean biomarker levels between gravity
drip and aspiration extraction methods (p > 0.05,
Table 3). For the individual biomarkers, BACE1 and
total Tau had p values closer to one (p > 0.9), indicating
smaller differences between extraction methods, while
all ratio biomarkers achieved similar performance (p > 0.9).
Similar to stratification by clinical classification, there
were no statistical differences in biomarker levels found
when stratifying data by PET-Aβ status (Supplementary
Figure 2).
Finally, we evaluated whether the observed differences
in biomarker concentrations between extraction
Table 2 Sub-cohort demographics
Total sample CN MCI AD p value
N (%) 50 36 (72) 8 (16) 6 (12)
PET-Aβ+ (%) 23 (46) 12 (35) 5 (71) 6 (100) 0.0029
Gender male, N (%) 21 (42) 14 (39) 3 (38) 4 (67) 0.54
Mean age, years (SD) 72.8 (5.8) 73.1 (5.6) 73.5 (7.3) 70.5 (5.3) 0.42
APOE ε4 carriage, N (%) 16 (32) 9 (25) 4 (50) 4 (50) 0.26
Median MMSE, (MAD) 28 (3) 29 (1.5) 27 (2.2) 23.5 (4.4) 0.0019
Median CDR score, (MAD) 0 (0) 0 (0) 0.5 (0) 1 (0.4) < 0.0001
Abbreviations: N number, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease, APOE ε4 Apolipoprotein E epsilon 4 allele, APOE ε4
Carriage, N (%) number of participants with at least one APOE ε4 allele, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, IQR inter-quartile
range, MAD maximum absolute deviation, PET-Aβ Positron Emission Tomography Amyloid Beta. p value determined by t-test (age), chi-square analyses (PET-Aβ
status, APOE ε4, and gender) and Kruskal-Wallis tests (CDR score and MMSE)
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methods (gravity drip, aspiration) are affected by the se-
lected biomarker or biomarker combination. Results are
presented in Fig. 4. While the overall change in concen-
tration between methods is limited, it is obvious from
the figure that the variation between subjects is much
lower for total Tau, α-synuclein, and Neurogranin as
compared to either Aβ proteins used as a single bio-
marker or when integrated into a ratio.
Outlier samples
Supplementary Table 1 shows the demographic and
clinical details for the participants who had CSF
values considered as outliers from either gravity drip
or aspiration extraction methods. Visualisation refers
to how the outlier was detected. For example, the
term “Box” refers to the outlier being detected from
the Box and Whisker plots (Fig. 3), while the term
Fig. 1 a–i Concordance correlation plots per biomarker. Black points represent data from positron emission tomography (PET)-Aβ− participants;
grey points represent data from PET-Aβ+ participants. Round points represent those participants who were cognitively normal (CN); square points
represent those participants with mild cognitive impairment (MCI); triangular points represent those participants with Alzheimer’s disease (AD).
The solid black line represents the concordance correlation (CC) between gravity and aspiration extraction methods. Aβ; amyloid beta, BACE1;
beta-secretase 1
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“BA” refers to the outlier being detected from the
Bland-Altman plot (Fig. 2). Here the outlier value
represents a large difference in the biomarker value
between extraction methods (i.e., the value lies out-
side the grey dashed lines). Outlier values depicted
here are also seen in Fig. 3, where outlier values are
consistent across extraction methods.
Discussions
In this study, we aimed to assess the concordance in
biomarker levels between gravity drip and aspiration
CSF extraction methods. After investigating each of six
individual and three ratio biomarkers using multiple
concordance methods, it is clear that biomarker reliabi-
lity is independent of CSF extraction method. For the
Fig. 2 a–i Bland Altman plots per biomarker. Black horizontal line represents the point at which the biomarker mean difference between
aspiration and gravity drip extraction methods is equal to zero. Lower grey dashed line represents the point at which the value on the y-axis is
1.96 standard deviations below zero. Upper grey horizontal dashed line represents the point at which the value on the y-axis is 1.96 standard
deviations above zero
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majority of biomarkers, concordance correlation co-
efficients were greater than 0.95, with reduction in
precision due to a few outliers and the small sample
size. Overall repeatability was consistent within both
the complete sample and across individual clinical
groups.
Assessment of biomarker outliers from both aspiration
and gravity drip extracted samples showed that outlier
values were independent of extraction method; i.e., the
reason for the aberrant biomarker level was unrelated to
extraction method. Furthermore, assessment of bio-
marker levels between extraction methods, stratified by
either clinical classification or by PET-Aβ status, did not
increase the variance in biomarker levels, strengthening
the claim of stability across a range of different clinical
or phenotypic populations.
Fig. 3 a–i Box and whisker plots of median biomarker levels between extraction method and clinical classification. Black boxes and points
represent data from samples extracted using the aspiration method. Grey boxes and points represent data from samples extracted using the
gravity drip method. Upper lines on each box represent the 3rd quartile, middle lines represent the median value, and the lower lines represent
the first 1st quartile
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The minimal changes across extraction methods seen
in most biomarkers, as compared to the variability be-
tween extraction methods for Aβ40 and Aβ42 (Fig. 4),
again reiterates the fact that Aβ is a more challenging
protein for analytical assays. The number of confound-
ing factors at the pre-analytical and analytical level that
affect Aβ levels in biological fluids is higher than for
other proteins. It is not clear precisely which confound-
ing factor(s) might contribute to the variance observed
in the current study. No gradient effect was observed in
CSF by Le Bastard et al. (2015) for Aβ42, total tau, and
pTau181P as measured by ELISA (n = 20) [37]. Some
gradient effect was seen with higher collection volumes
for CSF Aβ42 when analysed on an automated chemilu-
minesent platform [38]. The same paper provided evi-
dence that CSF-Aβ42 levels were stable if fresh samples
were processed within 2 h, followed by a freeze thaw
cycle. All AIBL samples were processed within 1 h post
collection. Samples were put on wet ice immediately
after collection before further processing. Further,
Darrow et al. (2020) also noted an effect from blood con-
tamination, especially in the thawed samples. Neverthe-
less, in this study blood contamination did not account for
the higher variances observed for Aβ40 or Aβ42 levels, as
verified by quantification of Hb concentrations in
each CSF sample. New experimental designs and testing
procedures are required to solve such dilemmas.
The method of CSF collection is an important step in
the pre-analytical handling of CSF samples. While some
investigators routinely use gravity drip, others use aspir-
ation. Gravity drip has the drawback of unpredictable
variation of collection times and may potentially take
considerably longer than aspiration, thereby reducing
feasibility in busy clinics. In dementia evaluation set-
tings, the longer duration of CSF acquisition can be a
particular problem for a patient with memory impair-
ment or dementia since repeated reassurance and explan-
ation may be required. Our results demonstrate that
syringe aspiration does not have a significant effect on
analyte concentrations and, therefore, should be acceptable
and allow predictable and more rapid CSF collection.
This report extends the data of Rembach et al. [17] by
utilising optimised assay formats and the inclusion of
other biomarker proteins which will become important
in future stratification of subjects within the several dis-
ease areas of neurodegeneration. Our report shows the
strong concordance of CSF biomarkers when CSF is col-
lected either by standard gravity drip or syringe aspir-
ation (Table 3). In particular, more rapid collection by
aspiration suggests that wider adoption of aspiration is
feasible and may become the preferred means of CSF
collection for the detection of AD CSF profiles. Shorter
duration (~ 10min from gravity drip to ~ 1min for
aspiration) should help increase acceptance both by
patients undergoing the procedure and also staff con-
ducting the LP Furthermore, it is our belief that the out-
comes from this study will be relevant to data generated
on other technology platforms.
Fig. 4 Error bar plot for the standardised difference in biomarker levels between extraction methods. Biomarker values were standardised by
removing the mean from each value and then dividing by the standard deviation. Normalised values of biomarkers tested from the gravity drip
extraction method were then removed from the values of biomarkers from the aspiration method for plotting. Error bars represent the difference
values from each participant, with the mid-point being the point between the minimum and maximum difference values
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Limitations
The current study is not without limitations. Firstly,
regarding the extractions, all aspirations were per-
formed subsequent to gravity drip collection as per
AIBL protocol. Although reversal of collection order
is thought unlikely to have any effect on biomarker
levels, this notion has not been formally tested. A
second limitation of this study was the relatively
small number of subjects included, with varying
number of samples per clinical classification. The
small sample size for participants with MCI/AD may
over represent the strength of the biomarker con-
cordance between extraction methods, and future re-
search needs to be performed with a larger sample
size to specifically test this. The results of this study
should therefore be interpreted in the context of
these limitations.
Conclusions
In summary, the current study provides strong evidence
that key CSF protein biomarker measurements are not
influenced by extraction through either the gravity drip
or aspiration method, and that CSF results utilising ei-
ther method are inter-changeable. Much time can po-
tentially be saved and subject burden reduced using the
syringe extraction approach compared to gravity drip.
Results of this study should be incorporated into the
new consensus guidelines for CSF collection, storage,
and analysis of biomarkers.
Abbreviations
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Additional file 1: Supplementary Table 1. Participant CSF value outliers.
CN: Cognitively Normal, MCI: Mild Cognitive Impairment, AD: Alzheimer’s
Disease, Box: Box and Whisker plot, BA: Bland Altman plot, Scatter: Scatter
plot, APOE: Apolipoprotein E ε4 allele (−ve: no ε4 alleles, +ve: at least one
ε4 allele), Aβ; Amyloid beta, BACE1; Beta-secretase 1, MMSE; Mini mental
score equivalent, CDR; Clinical dementia rating. *ID are random letters
given to participants to show where specific individuals were seen to
have more than one outlier. Visualisation: where outlier was seen in
manuscript figure. Values were considered outliers if they were either out-
side the dotted lines in the Bland Altman plot, or above/below the whis-
ker on the box and whisker plot, or sitting away from the main data
group in the scatter plots. Supplementary Figure 1. Passing Bablock re-
gression fits to biomarker data. Abbreviations: Aβ; Amyloid beta, BACE1;
Beta-secretase 1. Diagonal lines represent the slope as calculated via the
Passing Bablock method. Shaded grey areas represent the 95% confi-
dence interval as calculated via bootstrap resampling. Light grey dashed
line represents the identity line between bottom left and top right cor-
ners of the graph. Regression equation is shown in the top left for esti-
mation of the conversion of a data point from aspiration to convert to
the same scale as the gravity data point. For example, for any one point
on the line that represents a result from a gravity drip extraction for the
BACE1 biomarker, we would multiply the value by 1.02 and add the value
of − 49.87; e.g., 2000 × 1.02 + (− 49.87) = 1990. Supplementary Figure 2:
Box and whisker plots of median biomarker levels between extraction
methods and PET-Aβ status. Abbreviations: Aβ; Amyloid beta, BACE1;
Beta-secretase 1. Black boxes and points represent data from samples ex-
tracted using the aspiration method. Grey boxes and points represent
data from samples extracted using the gravity drip method. Upper lines
Table 3 Mean values of AD CSF biomarkers, gravity drip versus aspiration extraction method
All participants N = 50 Cognitively normal N = 36 Mild cognitive impairment
N = 8
Alzheimer’s disease N = 6
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Aspiration Gravity p value Aspiration Gravity p value Aspiration Gravity p value Aspiration Gravity p value
α-synuclein 2370 (861) 2370
(866)
1.00 2330 (850) 2330
(866)







Neurogranin 356 (162) 371 (174) 0.73 331 (166) 343 (174) 0.77 400 (126) 425 (161) 0.73 446 (154) 466 (158) 0.83


















BACE1 2250 (841) 2260
(813)
0.95 2240 (783) 2240
(765)

























Ratio/Tau* 1.97 (1.30) 2.00
(1.37)
0.93 2.34 (1.29) 2.38
(1.36)
0.90 1.15 (0.79) 1.21
(0.92)
0.89 0.82 (0.58) 0.75
(0.55)
0.83
Aβ42/Tau 1.39 (0.79) 1.42
(0.82)
0.96 1.64 (0.69) 1.67
(0.71)
0.84 0.92 (0.81) 0.93
(0.81)
0.99 0.51 (0.48) 0.53
(0.57)
0.96
Abbreviations: Aβ amyloid beta, AD Alzheimer’s disease, CSF cerebrospinal fluid, SD standard deviation, tTau total tau, N number of participants. All biomarker
values are expressed in pg/mL. * Ratio; Aβ42/40
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on each box represent the 3rd quartile, middle lines represent the me-
dian value and the lower lines represent the 1st quartile. All biomarker
comparisons between gravity drip and aspiration by PET Aβ status were
not significant (p > 0.05, data not shown).
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